Information Provided By: 
Fly News Breaks for November 11, 2015
ESRX, HZNP
Nov 11, 2015 | 14:01 EDT
Piper Jaffray analyst David Amsellem does not expect Horizon Pharma's (HZNP) issues with Express Scripts (ESRX) to impact the company's growth trajectory. Payors like Express Scripts may face backlash over limiting patient and physician choices by attacking specialty pharmacies, Amsellem tells investors in an intraday research note. He reiterates an Overweight rating on Horizon with a $43 price target. The stock is down 17% to $18.57 after Express Scripts ended its relationship with a specialty pharmacy used by the company, Linden Care.
News For HZNP;ESRX From the Last 2 Days
There are no results for your query HZNP;ESRX
